爱尔兰医疗技术公司Fire1 Fire1 筹集120M美元,用于临床试验一个新的心脏失灵监测装置。 Irish medtech firm Fire1 raises $120M for clinical trials of a new heart failure monitoring device.

爱尔兰医疗技术公司Fire1募集1.2亿美元, 用于临床试验, Fire1, an Irish medical technology firm, has raised $120 million to fund clinical trials for its new device aimed at improving heart failure management. 该装置包括在身体最大静脉内植入传感器以监测液体水平,目的是帮助病人从家中管理其病情,减少住院次数。 The device, which includes an implanted sensor in the body’s largest vein to monitor fluid levels, aims to help patients manage their condition from home, reducing hospital visits. Fire1于2014年在加利福尼亚成立, 将总部迁至爱尔兰, Founded in California in 2014, Fire1 moved its headquarters to Ireland and is now working to demonstrate the device's effectiveness through trials involving 800 patients.